GOLDEN-EURO
13.4.2021 17:31:13 CEST | Business Wire | Pressemeddelelse
Champagnen flyder, og fejringen er godt undervejs i Golden Euro-casinoet, efter en heldig spiller ramte jackpotten og landede en monstergevinst på 3.746.291 €.
Spillerens gevinst blev udløst på Realtime Gamings enormt populære spillemaskine Aztec Millions og er den største gevinst nogensinde, der er blevet registreret på det progressive jackpotspil og hos Golden Euro.
Den 49-årige spiller foretog en indbetaling med kreditkort på 27 € for at starte sin session og for at få Golden Euros højtelskede 50 % indbetalingsmatchbonus, hvilket gave hende derfor 54 € at spille med.
Men selve gevinsten kom fra en lille indsats på blot 5 €, som hun foretog på sin smartphone - efterhånden som hjulene stoppede og jackpotten blev udløst, blev spilleren øjeblikkeligt millionær.
Adrian Berger fra Golden Euro Casino udtalte: "Vi er superglade for, at en af vores spillere landende den største jackpotgevinst nogensinde på Realtime Gamings Aztec Millions.
"Jeg talte med spilleren kort tid efter at have bekræftet hendes gevinst, og hun var i den syvende himmel, selvom det faktum, at hun nu er multimillionær, endnu ikke er gået helt op for hende.
"Disse gevinster er lige præcis, hvad Golden Euro handler om – vi vil gerne give vores spillere en sjov og underholdende online casinooplevelse med livsændrende gevinster, der kun er ét spin væk.
"Jeg vil endnu en gang lykønske vores heldige spiller, og jeg glæder mig til at annoncere flere store vindere og jackpotvindere hos Golden Euro i de kommende måneder."
Aztec Millions-jackpotten er atter på højkant og har allerede rundet over 1 million euro, så husk at prøve lykken og se, om du bliver den næste Golden Euro-millionær.
Jackpotværdien stiger hurtigt, fordi det er en progressiv netværksjackpot, hvilket betyder, at alle spillere, som spiller spillet på tværs af alle de casinoer, som tilbyder spillet, bidrager til jackpottens samlede sum.
Aztec Millions kan spilles på Golden Euro via download, øjeblikkeligt spil og i mobilens webbrowser.
Golden Euro Casino blev grundlagt i 2012 og er siden blevet en af de mest populære sider takket være sit fantastiske udvalg af spil, generøse bonusser og venlige kundesupport.
SLUT
Afsenders bemærkning:
Om Golden Euro Casino:
https://www.goldeneuro.com/en/
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210413005871/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 10:00:00 CET | Press release
The two partners launch “Bianca”, the first large-scale digitalisation initiative in Italy focused on histopathological samples, aimed at training AI algorithms to support pathologists’ diagnostic activities. The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying
OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 10:00:00 CET | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with
New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 10:00:00 CET | Press release
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro
Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 10:00:00 CET | Press release
Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 09:15:00 CET | Press release
This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment OptionsOveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum